Proteome-based plasma biomarkers for Alzheimer's disease

Brain

Volumn 129, Issue 11, 2006, Pages 3042-3050

  Hye, A ^a   Lynham, S ^a   Thambisetty, M ^a   Causevic, M ^a   Campbell, J ^a   Byers, H L ^a   Hooper, C ^a   Rijsdijk, F ^a   Tabrizi, S J ^b   Banner, S ^a   Shaw, C E ^a   Foy, C ^a   Poppe, M ^a   Archer, N ^a   Hamilton, G ^a   Powell, J ^a   Brown, R G ^a   Sham, P ^a   Ward, M ^a   Lovestone, Simon ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; Biomarkers; Plasma; Proteomics; Two dimensional gel electrophoresis (2 DGE)

Indexed keywords

ALPHA 2 MACROGLOBULIN; BIOLOGICAL MARKER; COMPLEMENT FACTOR H; PROTEOME;

AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DISEASE SEVERITY; FEMALE; HUMAN; IMAGE ANALYSIS; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PLASMA; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEOMICS; SENSITIVITY AND SPECIFICITY; TWO DIMENSIONAL ELECTROPHORESIS;

AGED; AGED, 80 AND OVER; ALPHA-MACROGLOBULINS; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; BLOOD PROTEINS; CASE-CONTROL STUDIES; COMPLEMENT FACTOR H; DIAGNOSIS, DIFFERENTIAL; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; MALE; NEURODEGENERATIVE DISEASES; PROTEOME; PROTEOMICS; SENSITIVITY AND SPECIFICITY;

EID: 33750596715     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awl279     Document Type: Article

References (43)

1. Aliferis CF, Hardin D, Massion PP. Machine learning models for lung cancer classification using array comparative genomic hybridization. Proc AMIA Symp 2002. p. 7-11.
2. Armstrong PB, Quigley JP. A role for protease inhibitors in immunity of long-lived animals. Adv Exp Med Biol 2001; 484: 141-60.
3. Baird PN, Guida E, Chu DT, Vu HT, Guymer RH. The epsilon2 and epsilon4 alleles of the apolipoprotein gene are associated with agerelated macular degeneration. Invest Ophthalmol Vis Sci 2004; 45: 1311-5.
4. Bauer J, Strauss S, Schreiter Gasser U, Ganter U, Schlegel P, Witt I, et al. Interleukin-6 and alpha-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices. FEBS Lett 1991; 285: 111-4.
5. Bertram L, McQueen M, Mullin K, Blacker D, Tanzi R. 2005.
6. Biroccio A, Del BP, Panella M, Bernardini S, Di Ilio C, Gambi D, et al. Differential post-translational modifications of transthyretin in Alzheimer's disease: a study of the cerebral spinal fluid. Proteomics 2006; 6: 2305-13.
7. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003; 2: 605-13.
8. Cucullo L, Marchi N, Marroni M, Fazio V, Namura S, Janigro D. Blood-brain barrier damage induces release of alpha2-macroglobulin. Mol Cell Proteomics 2003; 2: 234-41.
9. D'Andrea MR. Add Alzheimer's disease to the list of autoimmune diseases. Med Hypotheses 2005; 64: 458-63.
10. DeKosky ST, Ikonomovic MD, Wang X, Farlow M, Wisniewski S, Lopez OL, et al. Plasma and cerebrospinal fluid alpha1-antichymotrypsin levels in Alzheimer's disease: correlation with cognitive impairment. Ann Neurol 2003; 53: 81-90.
11. Edwards AO, Ritter R III, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science 2005; 308: 421-4.
12. Esparza-Gordillo J, Soria JM, Buil A, Almasy L, Blangero J, Fontcuberta J, et al. Genetic and environmental factors influencing the human factor H plasma levels. Immunogenetics 2004; 56: 77-82.
13. Finehout EJ, Franck Z, Lee KH. Complement protein isoforms in CSF as possible biomarkers for neurodegenerative disease. Dis Markers 2005; 21: 93-101.
14. Hageman GS, Anderson DH, Johnson LV, Hancox LS, Taiber AJ, Hardisty LI, et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci USA 2005; 102: 7227-32.
15. Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, Gallins P, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 2005; 308: 419-21.
16. Hampel H, Kotter HU, Padberg F, Korschenhausen DA, Moller HJ. Oligoclonal bands and blood-cerebrospinal-fluid barrier dysfunction in a subset of patients with Alzheimer disease: comparison with vascular dementia, major depression, and multiple sclerosis. Alzheimer Dis Assoc Disord 1999; 13: 9-19.
17. Hampel H, Muller-Spahn F, Berger C, Haberl A, Ackenheil M, Hock C. Evidence of blood-cerebrospinal fluid-barrier impairment in a subgroup of patients with dementia of the Alzheimer type and major depression: a possible indicator for immunoactivation. Dementia 1995; 6: 348-54.
18. Hampel H, Mitchell A, Blennow K, Frank RA, Brettschneider S, Weller L, et al. Core biological marker candidates of Alzheimer's disease-perspectives for diagnosis, prediction of outcome and reflection of biological activity. J Neural Transm 2004; 111: 247-72.
19. Irizarry MC. Biomarkers of Alzheimer disease in plasma. Neurorx 2004; 1: 226-34.
20. Johnson LV, Leitner WP, Rivest AJ, Staples MK, Radeke MJ, Anderson DH. The Alzheimer's A beta-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc Natl Acad Sci USA 2002; 99: 11830-5.
21. Klaver CC, Ott A, Hofman A, Assink JJ, Breteler MM, de Jong PT. Is age-related maculopathy associated with Alzheimer's disease? The Rotterdam study Am J Epidemiol 1999; 150: 963-8.
22. Liu HC, Hu CJ, Chang JG, Sung SM, Lee LS, Yuan RY, et al. Proteomic identification of lower apolipoprotein A-I in Alzheimer's disease. Dement Geriatr Cogn Disord 2006; 21: 155-61.
23. Loeffler DA, DeMaggio AJ, Juneau PL, Brickman CM, Mashour GA, Finkelman JH, et al. Ceruloplasmin is increased in cerebrospinal fluid in Alzheimer's disease but not Parkinson's disease. Alzheimer Dis Assoc Disord 1994; 8: 190-7.
24. Lopez MF, Mikulskis A, Kuzdzal S, Bennett DA, Kelly J, Golenko E, et al. High-resolution serum proteomic profiling of Alzheimer disease samples reveals disease-specific, carrier-protein-bound mass signatures. Clin Chem 2005; 51: 1946-54.
25. Mattila KM, Frey H. Two-dimensional analysis of qualitative and quantitative changes in blood cell proteins in Alzheimer's disease: search for extraneuronal markers. Appl Theor Electrophor 1995; 4: 189-96.
26. Mehta PD, Dalton AJ, Mehta SP, Percy ME, Sersen EA, Wisniewski HM. Immunoglobulin G subclasses in older persons with down syndrome. J Neurol Sci 1993; 117: 186-91.
27. Mullins RF, Russell SR, Anderson DH, Hageman GS. Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB J 2000; 14: 835-46.
28. Nath A, Hall E, Tuzova M, Dobbs M, Jons M, Anderson C, et al. Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheimer's disease patients and Abeta antibodies can enhance Abeta neurotoxicity: implications for disease pathogenesis and vaccine development. Neuromol Med 2003; 3: 29-39.
29. Newsome DA, Swartz M, Leone NC, Hewitt AT, Wolford F, Miller ED. Macular degeneration and elevated serum ceruloplasmin. Invest Ophthalmol Vis Sci 1986; 27: 1675-1680.
30. Reisberg B, Ferris SH, De Leon MJ, Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982; 139: 1136-9.
31. Rodriguez de Cordoba S, Esparza-Gordillo J, Goicoechea de Jorge E, Lopez-Trascasa M, Sanchez-Corral P. The human complement factor H: functional roles, genetic variations and disease associations. Mol Immunol 2004; 41: 355-67.
32. Scacchi R, Ruggeri M, Gambina G, Martini MC, Corbo RM. Alpha2-macroglobulin deletion polymorphism and plasma levels in late onset Alzheimer's disease. Clin Chem Lab Med 2002; 40: 333-6.
33. Strauss S, Bauer J, Ganter U, Jonas U, Berger M, Volk B. Detection of interleukin-6 and alpha 2-macroglobulin immunoreactivity in cortex and hippocampus of Alzheimer's disease patients. Lab Invest 1992; 66: 223-30.
34. Strohmeyer R, Shen Y, Rogers J. Detection of complement alternative pathway mRNA and proteins in the Alzheimer's disease brain. Brain Res Mol Brain Res 2000; 81: 7-18.
35. Strohmeyer R, Ramirez M, Cole GJ, Mueller K, Rogers J. Association of factor H of the alternative pathway of complement with agrin and complement receptor 3 in the Alzheimer's disease brain. J Neuroimmunol 2002; 131: 135-46.
36. Sunderland T, Gur RE, Arnold SE. The use of biomarkers in the elderly: current and future challenges. Biol Psychiatry 2005; 58: 272-6.
37. Szafranski C, Bailey J, Turck CJ, Nicol G, Martosella J, Zolotarjova N. Enhancing analytical access to low abundant proteins in the human plasma proteome. 2004. p. 40-6.
38. Tam SW, Pirro J, Hinerfeld D. Depletion and fractionation technologies in plasma proteomic analysis. Expert Rev Proteomics 2004; 1: 411-20.
39. Yang ZR, Chou KC. Bio-support vector machines for computational proteomics. Bioinformatics 2004; 20: 735-41.
40. Yocum AK, Yu K, Oe T, Blair IA. Effect of immunoaffinity depletion of human serum during proteomic investigations. J Proteome Res 2005; 4: 1722-31.
41. Zhang R, Barker L, Pinchev D, Marshall J, Rasamoelisolo M, Smith C, et al. Mining biomarkers in human sera using proteomic tools. Proteomics 2004; 4: 244-56.
42. Zipser BD, Johanson CE, Gonzalez L, Berzin TM, Tavares R, Hulette CM, et al. Microvascular injury and blood-brain barrier leakage in Alzheimer's disease. Neurobiol Aging 2006. In press.
43. Zolotarjova N, Martosella J, Nicol G, Bailey J, Boyes BE, Barrett WC. Differences among techniques for high-abundant protein depletion. Proteomics 2005; 5: 3304-13.